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ABSTRACT
Purpose: To better understand the molecular mecha-
nisms that underlay the development and progression of
nonseminomatous germ cell tumor of testis (NSGCTT) as
well as malignant transformation of teratoma and primitive
neuroectodermal tumor (PNET).
Experimental Design: We studied the gene expression
profiles of 17 retroperitoneal NSGCTTs (10 yolk sac tumors,
3 embryonal carcinomas, 4 teratomas) and 2 PNETs ob-
tained from patients with two clinical outcomes. Tissue sam-
ples were obtained from the Indiana University. One group
of NSGCTT and PNET patients developed metastases
within 2 years (early-relapse) of initial successful treatment,
and the other group developed metastases after 2 years
(late-relapse). Gene expression in these groups of patients
was quantified using cDNA microarrays and real-time rel-
ative quantitative PCR.
Results: We demonstrate that the gene expression pro-
files of these tumors correlate with histological type. In
addition, we identify type-specific genes that may serve as
novel diagnostic markers. We also identify a gene set that
can distinguish between early-relapse and late-relapse yolk
sac tumors. The expression differences of these genes may
underlie the differences in clinical outcome and drug re-
sponse of these tumors.
Conclusion: This is the first study that used gene ex-
pression profiling to examine the molecular characteristics
of the NSGCTTs and drug response in early- and late-
relapse tumors. These results suggest that two molecularly
distinct forms of NSGCTTs exist and that the integration of
expression profile data with clinical parameters could en-
hance the diagnosis and prognosis of NSGCTTs. More im-
portantly, the identified genes provide insight into the mo-
lecular mechanisms of aggressive NSGCTTs and suggest
intervention strategies.
INTRODUCTION
Testicular cancer is a relatively rare malignancy; however,
an estimated 7,400 new cases were reported in the United States
in 1999, and it is the most common cancer of men between the
ages of 15 and 34 (1, 2). Based on morphological features, germ
cell tumors are divided into seminoma, yolk sac tumor, embry-
onal carcinoma, choriocarcinoma, and teratoma according to the
WHO International Histological Classification of Testicular Tu-
mors (3). Non-germ-cell malignancies such as primitive neuro-
ectodermal tumors (PNETs) arise in testicular germ cell tera-
toma and are associated with an increased number of relapses
and a decreased relapse-free and overall survival (4). Teratoma
is pluripotential tissue that can differentiate along ectodermal,
endodermal, or mesodermal elements. PNET represents malig-
nant transformation of teratoma along mesodermal lines.
Testicular cancer has a 95% cure rate, and most relapses
occur within the first 2 years of therapy. Only 2–3% of patients
treated for testicular cancer have late-relapse (defined as recur-
rence 2 years after initial successful therapy). Metastatic germ
cell tumors have remarkably high cure rates. However, those
with late relapse are found to be refractory to chemotherapy and
carry a poor prognosis (5). Cytogenetic studies suggest most
testicular tumors contain extra copies of the short arm of chro-
mosome 12, and this genomic alteration may be responsible for
the development of testicular neoplasms (6). Unfortunately,
many of these additional differences remain unknown. How-
ever, differences in chemosensitivity and survival are most
likely related to additional differences in underlying genetic and
biological characteristics.
Microarray technology has provided new insights into the
underlying molecular mechanisms of many types of cancers.
The gene expression profiles from microarrays can identify the
molecular signatures of cancers and can be used to distinguish
histological types and to discover novel types. Classification of
tumors by gene expression may reflect heterogeneity in trans-
formation mechanisms, cell types, or aggressiveness among
tumors. Furthermore, several studies have identified prognostic
sets of genes that may underlie the heterogeneity in tumor
aggressiveness (7–10). The identification of such genes may
lead to the discovery of new potential targets for cancer diag-
nosis and therapy. Recently, differentially expressed genes on
chromosome 17 in 18 testicular samples (15 germ cell tumors;
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3 normal testes) were identified using a microarray contain-
ing 636 cDNA. Growth factor receptor-bound protein 7 and
junction plakoglobin at the 17q11– q21, lethal giant larvae
homologue 2, and phosphodiesterase 6G at the 17q24 – qter
were consistently the most up-regulated in the testicular
tumors (11, 12). However, no study has identified a prognos-
tic set of genes.
In this study, we characterized the molecular signature of
17 metastatic regions of nonseminomatous germ cell tumors of
testes (NSGCTTs) and two PNETs by using 19,968 cDNA
microarrays to elucidate their underlying molecular mecha-
nisms. Furthermore, we sought to identify a gene set that can
distinguish between early-relapse and late-relapse tumors and
correlate with differences in survival and chemosensitivity.
MATERIALS AND METHODS
Patient Information and Tumor Samples. Tissue sam-
ples were obtained from 19 patients with metastatic lesions
(NSGCTTs and PNETs) of the testis. The patients had under-
gone retroperitoneal lymph node dissection after chemotherapy
at Indiana University. Nine patients had early relapse (within 2
years of initial management), whereas 10 had late relapse (after
2 years of initial management). Informed consent was obtained
from patients to use their removed tissue specimens and clini-
copathological data for research purposes. Approval was ob-
tained by the Indiana University Internal Review Boards. The
samples were rendered anonymous before the study. Part of
each tumor sample was frozen immediately after the operation
and stored at 80°C. Total RNA was isolated from the frozen
tissue by using TRIzol reagent (Invitrogen, Carlsbad, CA). For
all samples, total RNA was purified with 2.5 M final concentra-
tion of LiCl. The remaining parts of tumors were fixed with 10%
buffered formalin, and the paraffin sections were stained with
H&E. The WHO International Histological Classification of
Tumors was used for histological evaluation of the specimens
(3). Union Internationale Contre le Cancer Tumor-Node-Metas-
tasis classification and stage groupings were also used (13).
cDNA Microarray Fabrication and Procedures. Mi-
croarray production was performed as described previously (14,
15) with slight modification. Briefly, 19,968 cDNA clones were
PCR-amplified directly from bacterial stocks purchased from
Research Genetics (Huntsville, AL). Following ethanol precip-
itation and transfer to 384-well plates, clones were printed onto
aminosilane-coated glass slides using a custom-built robotic
microarrayer. Normal human testicle total RNA (Ambion, TX)
purified with 2.5 M final concentration of LiCl was used as a
reference. For all samples, 50 g of total RNA from tumors and
reference were reverse-transcribed with oligodeoxythymidylic
acid primer and Superscript II (Invitrogen) in the presence of
Cy5-dCTP and Cy3-dCTP (Amersham Pharmacia Biotech, Pea-
Table 1 Differentially expressed genes in yolk sac tumor
Accession ID Gene name Fold changea P
N62394 Gap junction protein,  1, 32kD 6.5 0.0047
H59861 Thrombomodulin (THBD) 6.4 0.0350
AA775872 Glypican 3 4.2 0.0300
AA148737 Syndecan 4 (amphiglycan, ryudocan) 4.1 0.0062
R10382 Serine (or cysteine) proteinase inhibitor, clade A, member 5 4.1 0.0220
AA431347 GATA-binding protein 4 3.9 0.0017
H77652 GATA-binding protein 6 3.9 0.0036
AA858026 Serine (or cysteine) proteinase inhibitor, clade A, member 5 3.9 0.0230
N26536 ATPase, Cu transporting, beta polypeptide 3.2 0.0023
N38992 GATA-binding protein 4 3.1 0.0066
N53172 G protein-coupled receptor 3.1 0.0058
AA457700 Stearoyl-CoA desaturase 3.0 0.0044
AA452840 Fibulin 2 2.9 0.0120
AA001614 Insulin receptor 2.8 0.0180
AA487149 Numb (Drosophila) homolog 2.8 0.0088
R02036 KIAA1543 protein 2.7 0.0370
AA406266 Hypothetical protein FLJ23309 2.2 0.0170
AA490216 CK2 interacting protein 1; HQ0024c protein 2.4 0.0180
AA701933 CUG triplet repeat, RNA-binding protein 2 2.4 0.0290
AA459394 LIS1-interacting protein NUDE1, rat homolog 2.6 0.0500
AA863383 pim-2 oncogene 2.7 0.0360
N39240 Homo sapiens cDNA FLJ11918 fis, clone HEMBB1000272 3.1 0.0034
AA455925 Four and a half LIM domains 1 3.1 0.0190
AA047478 Coronin, actin-binding protein, 1A 3.5 0.0220
AA157813 Interferon,  inducible protein 27 3.6 0.0096
R06438 Homo sapiens cDNA: FLJ22300 fis, clone HRC04759 3.7 0.0036
H73590 IMMUNOGLOBULIN HEAVY CHAIN-RELATED 4.0 0.0086
T67053 Immunoglobulin -like polypeptide 1 6.6 0.0091
AA663981 Immunoglobulin heavy constant  3 6.9 0.0460
AA488070 Immunoglobulin  constant 7.4 0.0260
N92646 Acyl-Coenzyme A dehydrogenase, C-2 to C-3 short chain 7.4 0.0330
a Fold change indicates yolk sac tumors have relatively higher or lower expression of this fold change compared to other types of
nonseminomatous germ cell tumor of testes and primitive neuroectodermal tumors studied.
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pack, NJ). The Cy5- and Cy3-labeled cDNA probes were mixed
with probe hybridization solution containing formamide and
hybridized to pre-warmed (50°C) slides for 20 h at 50°C.
Following hybridization, slides were washed, dried by snap
centrifugation, and scanned immediately using Scan Array Lite
operating at 532 and 635 nm (GSI Lumonics, Billerica, CA).
Data Analysis. Images were analyzed by using the soft-
ware GENEPIX PRO 3.0 (Axon Instruments, Foster City, CA).
Spots showing no signal or obvious defects were excluded from
the analysis. The local background was subtracted from the
remaining spots, and the ratios of net fluorescence from the
Cy5-specific channel to the net fluorescence from the Cy3-
specific channel were calculated for each spot, representing
tumor RNA expression relative to the normal testicular total
RNA.
Microarray Analysis. Two sources of systematic bias
were reduced in the data by normalization. Loess regression was
performed on the log-transformed data to eliminate the intensi-
ty-dependent variation in the ratio of the spot intensities that has
been observed in gene expression data (16, 17). This normal-
ization was performed in a pin-dependent fashion to further
reduce systematic variation related to the physical properties of
each pin of the slide-spotting robot. Following loess normaliza-
tion, the data were median-centered and rescaled using the
median absolute deviation as described elsewhere (18, 19).
These normalizations were carried out using the Bioconductor
package7 for the R statistical analysis framework (20). Unsu-
pervised clustering was performed on the normalized data using
CLUSTER and visualized using TREEVIEW.8 The significance
threshold was set at P 	 0.05, and only those genes for which
data were available in 75% of all 19 cases (i.e., at least 15 in all)
were included in the analysis (4,569 genes). Because the cases
initially clustered according to histological type, indicating
unique genetic signatures among the types, it was decided that
the histological types should not be combined for the purpose of
determining possible genetic predictors of outcome (early-re-
lapse versus late-relapse). However, with the exception of yolk
sac tumors, there were not enough cases within each histological
type to perform this analysis. Therefore, the analysis of genes
related to outcome was restricted to the yolk sac tumors.
Differentially expressed genes were identified using the
Cluster Identification Tool application (21), which compares the
mean expression in each group and uses random permutation to
estimate P. Because of the possibility of false discovery, we
selected the two differentially expressed genes in late-relapse
NSGCTTs and four differentially expressed genes in late-re-
7 http://www.bioconductor.org.
8 MB Eisen; http://rana.lbl.gov.
Table 2 Differentially expressed genes in embryonal carcinoma
Accession ID Gene name Fold changea P
N92646 Acyl-Coenzyme A dehydrogenase, C-2 to C-3 short chain 12.1 0.0260
AA663981 Immunoglobulin heavy constant  3 10.1 0.0430
AA419251 Interferon induced transmembrane protein 1 9.4 0.0003
AA488070 Immunoglobulin  constant 8.2 0.0470
W73144 Lymphocyte cytosolic protein 1 (L-plastin) 8.0 0.0004
AA863383 pim-2 oncogene 7.2 0.0007
H73590 IMMUNOGLOBULIN HEAVY CHAIN-RELATED 7.2 0.0005
AA047478 Coronin, actin-binding protein, 1A 7.0 0.0004
T67053 Immunoglobulin -like polypeptide 1 6.5 0.0300
N53214 RIBONUCLEASE INHIBITOR-RELATED 6.4 0.0066
AA406020 Interferon-stimulated protein, 15 kDa 5.8 0.0002
AA058323 Interferon-induced transmembrane protein 1 5.7 0.0003
H77597 Metallothionein 1H 5.2 0.0067
AA157813 Interferon, -inducible protein 27 5.0 0.0042
N30205 ESTs 4.4 0.0120
AA599094 KELCH-RELATED 3.7 0.0021
AA453170 Hypothetical protein FLJ14299 3.9 0.0032
W87528 Nuclear factor I/B 3.9 0.0180
R42421 Cdc42 effector protein 2 4.0 0.0120
H12784 ESTs 4.2 0.0012
AA488636 KIAA0878 protein 4.9 0.0005
AA148737 Syndecan 4 (amphiglycan, ryudocan) 5.0 0.0170
AA496878 Hypothetical protein FLJ22041 similar to FK506 binding proteins 5.1 0.0002
N53172 G protein-coupled receptor 5.4 0.0110
AA464250 Keratin 19 6.5 0.0280
AA131299 Hypothetical protein PRO1489 7.3 0.0029
W60582 Uncharacterized hypothalamus protein HBEX2 7.5 0.0071
H77652 GATA-binding protein 6 8.9 0.0015
N62394 Gap junction protein,  1, 32kD 9.0 0.0092
AA775872 Glypican 3 11.0 0.0021
a Fold change indicates embryonal carcinomas have relatively higher or lower expression of this fold change compared to other types of
nonseminomatous germ cell tumor of testes and primitive neuroectodermal tumors studied.
2370 Profiling of Testicular Germ Cell Tumors
Cancer Research. 
on February 4, 2021. © 2004 American Association forclincancerres.aacrjournals.org Downloaded from 
lapse yolk sac tumors identified by this method and confirmed
their expression level using real-time PCR.
Comparative Genomic Microarray Analysis Algorithm.
To identify regional gene expression biases, gene expression
values that map to a given chromosomal arm are collected, and
a binomial test is used to determine if a significant upward or
downward bias is present. First, sequence comparisons are used
to map microarray probe sequences (the sequences that are
placed on the microarray) to predicted Ensembl transcripts
(Ensembl version 10.2; Ref. 22). Included in the Ensembl tran-
script annotations are chromosomal mapping locations at base-
pair resolution. Expression values from multiple probes that
map to the same gene are condensed to a single value by
averaging. To apply the binomial test to expression data, of n
non-zero expression values that map to a given chromosomal
arm, r gene expression values are scored as “up” if the
log2(R/G) value is positive and (n  r) “down” if the log-
transformed ratio is negative. This binomial test assumes that in
a cytogenetically normal genomic region, the probability of a
gene expression value being positive (p) is equal to the proba-
bility of the expression value being negative (q) such that p 

q 
 0.5. For the binomial test, the probability of obtaining r
“up” observations with a probability p and n  r “down”
observations with a probability q is
Prbinomial  nCr*p
r*qnr  n!prqnr/r!n  r!.
In the cases where n  25 and n*p*q  10, the binomial
probability density function is approximated using the normal
probability density function, and a z-statistic for the chromo-
somal arm is computed such that z 
 (2r  n)/sqrt(n). There-
fore, a large positive z-statistic indicates a significant positive
expression bias (i.e., genomic gain), and a large negative z-
statistic indicates the presence of a negative expression bias (i.e.,
genomic loss). A set of chromosomal arm z-statistics can be
plotted as a heat map to identify and summarize predicted
cytogenetic features (23).
Real-Time Relative Quantitative PCR (RT-PCR). RT-
PCR was performed in triplicate using the ABI PRISM 7700
Sequence Detection System according to the manufacturer’s
instructions, and these data were averaged. The two primers and
the TaqMan probe were specifically designed for the following
six genes: glutathione S-transferase 1 (GSTT1); fatty acid
synthase (FASN); phospholipase A2 group IIA (PA2IIA); trinu-
cleotide repeat containing 3 (TNRC3); glypican 3 (GPC3); and
glutaredoxin (GLRX) using Primer Express v1.5a (Applied Bio-
systems, Foster City, CA).
One hundred ng of each cDNA were amplified using PCR
Master Mix according to the following PCR conditions: 50°C
for 2 min; 95°C for 10 min; followed by 40 cycles of 95°C for
15 s; and 60°C for 1 min. Because 18S rRNA resulted in the
least variation throughout the samples among a total of 11
housekeeping genes using Taqman Human Endogenous Control
Plate (Applied Biosystems), this gene was used as the endoge-
nous control. Each threshold cycle (CT), which indicates the
cycle at which an increase in reporter fluorescence just goes
over the optimal value line, was determined. The CT value of
Table 3 Differentially expressed genes in teratoma
Accession ID Gene name Fold changea P
AA155913 Matrix Gla protein 7.4 0.0120
AA459308 Elastin (supravalvular aortic stenosis, Williams-Beuren syndrome) 7.1 0.0003
R06438 Homo sapiens cDNA: FLJ22300 fis, clone HRC04759 7.0 0.0059
AA126989 Myosin, heavy polypeptide 11, smooth muscle 6.9 0.0020
AA459394 LIS1-interacting protein NUDE1, rat homolog 6.1 0.0018
AA156947 Sirtuin 4 5.4 0.0017
AA488073 Mucin 1, transmembrane 4.7 0.0190
N91811 ESTs 4.4 0.0200
AA134871 Fibulin 1, transcript variant D 4.3 0.0120
AA455925 Four and a half LIM domains 1 4.3 0.0140
R09729 Serum deprivation response 4.2 0.0025
AA496022 Microfibrillar-associated protein 4 4.1 0.0091
AA070226 Selenoprotein P, plasma, 1 4.0 0.0027
AA463926 Protein phosphatase 1, regulatory (inhibitor) subunit 4.0 0.0050
R67283 ESTs 3.9 0.0005
AA478066 Membrane-associated tyrosine- and threonine-specific 2.7 0.0002
N70010 Homo sapiens, similar to RIKEN cDNA 2610036L13 gene 2.7 0.0078
AA873159 Apolipoprotein C-I 2.7 0.0460
AA663995 Minichromosome maintenance deficient (mis5, S. pombe) 2.8 0.0012
AA682321 NIMA (never in mitosis gene a)-related kinase 2 2.8 0.0054
AA071486 Serine/threonine kinase 12 2.9 0.0013
AA629262 Polo (Drosophia)-like kinase 2.9 0.0056
AA457034 V-myb avian myeloblastosis viral oncogene homolog-like 2 2.9 0.0280
H59260 Cell division cycle 25A 3.0 0.0063
AA448261 High-mobility group protein 3.0 0.0130
AA419177 Solute carrier family 7, member 5 3.0 0.0490
AA446462 Budding uninhibited by benzimidazoles 1 3.1 0.0024
N30069 ESTs 3.1 0.0150
AA136566 Forkhead box M1 3.4 0.0014
R00707 Stearoyl-CoA desaturase (-9-desaturase) 3.7 0.0140
a Fold change indicates teratomas have relatively higher or lower expression of this fold change compared to other types of nonseminomatous
germ cell tumor of testes and primitive neuroectodermal tumor studied.
2371Clinical Cancer Research
Cancer Research. 
on February 4, 2021. © 2004 American Association forclincancerres.aacrjournals.org Downloaded from 
18S rRNA was subtracted from each CT value of tumor or
normal for normalization, and the ratio of tumor to normal
testicular RNA expression was calculated to compare with mi-
croarray data.
RESULTS
Gene Expression Profiling. We analyzed the gene ex-
pression profiling data in two ways. First, we compared the gene
expression of each tumor sample with normal testicular RNA to
identify gene expression alterations that occur in NSGCTT and
PNET. In addition, we identified particular subsets of genes that
most strongly distinguished between late- and early-relapse pa-
tients.
Differentially expressed cDNAs in each type of tumors are
listed in Tables 1-4. They are significantly up-regulated or
down-regulated in each type of tumors compared to other types
of tumors. A patient dendrogram based on a set of differentially
expressed genes in each of the tumors compared with all other
types of NSGCTTs (or PNETs) studied was shown in Fig. 1A.
All differentially expressed cDNA in late-relapse tumors com-
pared to early-relapse tumors and all differentially expressed
cDNA in late-relapse yolk sac tumors compared to early-relapse
yolk sac tumors are listed in Tables 5 and 6. A patient dendro-
gram based on the whole differentially expressed 13 cDNA set
that might distinguish the late-relapse group from the early-
relapse group is shown in Fig. 1B.
Real-Time Relative Quantitative PCR. Six genes were
selected to confirm the microarray results with RT-PCR. To
compare the gene expression ratios obtained by microarray to
the RT-PCR data, the expression ratio of tumor to noncancerous
testis was calculated by RT-PCR (Fig. 2). RT-PCR showed a
significantly higher expression ratio of GSTT1 (P 
 0.016) in
late-relapse yolk sac tumors (Fig. 2A) but not FASN (P 
 0.222,
Fig. 2B). PA2IIA and TNRC3 were significantly under expressed
in late-relapse yolk sac tumors (P 
 0.032 and 0.016, respec-
tively; Fig. 2, C and D), and PA2IIA was more highly expressed
in early-relapse yolk sac tumors. GPC3 and GLRX did not have
significant changes (P 
 0.310 and 0.548, respectively; Fig. 2,
E and F).
Chromosomal Changes. We also used the gene expres-
sion profiles to infer chromosomal abnormalities in these sam-
ples. Chromosomal changes identified in our study are shown in
Fig. 3. Frequent chromosomal changes of 6 and 12, as reported
previously in NSGCTTs were confirmed. In addition, a novel
chromosome change of 14q was frequently indicated by com-
parative genomic microarray analysis among late-relapse tumor
in this study.
DISCUSSION
Differentially Expressed Genes in Each Type of NSGCTT.
Identifying differentially expressed genes based on histological
diagnosis may lead to the discovery of new markers for differ-
Table 4 Differentially expressed genes in primitive neuroectodermal tumor
Accession ID Gene name Fold changea P
AA683041 Neuronal pentraxin II 12.0 0.0110
AA670438 Ubiquitin carboxyl-terminal esterase L1 10.1 0.0052
H24007 KIAA1878 protein 9.8 0.0040
AA129861 KIAA1878 protein 9.4 0.0051
AA019748 Aryl-hydrocarbon receptor nuclear translocator 2 6.3 0.0052
AA670382 H.sapiens mRNA for 3UTR of unknown protein 5.5 0.0170
N21633 ESTs 5.3 0.0160
AA435948 Heat shock 40kD protein 1 5.0 0.0230
AA454215 NDRG family, member 4 5.0 0.0160
AA775957 ATPase, Na/K transporting,  3 polypeptide 4.8 0.0170
AA137072 ESTs 4.8 0.0052
N50428 Hypothetical protein FLJ10582 4.4 0.0039
AA463251 Nucleosome assembly protein 1-like 3 4.4 0.0096
N66104 Kinesin family member 5C 4.2 0.0100
R74171 KIAA0871 protein 4.1 0.0052
AA099820 ESTs 4.8 0.0240
AA465521 SMC (mouse) homolog, Y chromosome 5.3 0.0170
AA412053 CD9 antigen (p24) 5.6 0.0310
AA431347 GATA-binding protein 4 5.9 0.0062
T73468 Glutathione S-transferase A2 5.9 0.0180
H06273 Keratin 8 6.1 0.0100
AA872020 Protease, serine, 8 (prostasin) 6.1 0.0052
W37780 Hypothetical protein 7.0 0.0038
T73090 Plasminogen 7.4 0.0280
AA430665 Claudin 4 7.5 0.0330
AA148737 Syndecan 4 (amphiglycan, ryudocan) 7.6 0.0076
AA598517 Keratin 8 9.4 0.0052
N62394 Gap junction protein,  1, 32kD 9.6 0.0190
N53214 RIBONUCLEASE INHIBITOR-RELATED 12.3 0.0048
AA458849 Serine protease inhibitor, Kunitz type, 2 14.1 0.0041
a Fold change indicates primitive neuroectodermal tumors have relatively higher or lower expression of this fold change compared to other types
of nonseminomatous germ cell tumor of testes studied.
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ential diagnosis. Because global clustering analysis using 4,569
cDNAs showed that each type of NSGCTT had distinct molec-
ular signatures, we sought to identify the differentially ex-
pressed genes contributing to these distinctions. However, the
combination of teratoma and yolk sac tumor is quite common as
is the combination of embryonal carcinoma and yolk sac tumor.
These combinations may affect gene expression, therefore we
will require a more detailed pathological review of those spec-
imens that cluster with other tumor types.
Generally, while some immunoglobulin genes and immu-
nological-related genes are differentially expressed in yolk sac
tumors (Table 1), a large number of immunoglobulin genes,
including IFN-related genes, are found in embryonal carcinomas
(Table 2). The possibility exists that immunological response to
the tumor may be important or that embryonal carcinoma is
more immunogenic than yolk sac tumors. Differentially ex-
pressed genes in teratoma (Table 3) include proteins such as
mucin, elastin, matrix protein, and fibulin, all of which are
structural proteins and would be consistent with the type of
histological characterization of well-differentiated teratoma.
Similarly, the differentially expressed genes in PNET (Table 4)
do not display any patterns other than relatedness to neuronal
tissue (see below).
If we concentrate on individual genes, gap junction protein
Fig. 1 Panel A, hierarchical clustering of 19 testicular tumors. Hierarchical clustering of the gene expression profiles of testicular tumors. Rows
represent individual cDNAs, and columns represent individual tumor samples. The color of each square represents the median-polished, normalized,
log-transformed gene expression ratio (tumor versus reference). Expression levels greater than the median are shaded in red, those below the median,
green; equal to the median, black; and inadequate or missing data, gray. The color saturation indicates the degree of divergence from the median.
Clustering is based on a combined set of genes that are unique to each subtype (total 543 cDNA). Basically, there are two main groups; one group
consists of embryonal carcinomas and teratomas, and the other consists of yolk sac tumors and primitive neuroectodermal tumor. The highly-expressed
genes from each tumor type are shown using sidebars with different colors (A, yolk sac tumor; B, teratoma; C, embryonal carcinoma; D, primitive
neuroectodermal tumor). Panel B, clustering of 10 yolk sac tumors. Clustering based on 13 differentially expressed cDNAs that discriminate between
late-relapse and early-relapse samples is shown in Fig. 1B. A, genes mostly over-expressed in tumors with the late relapse yolk sac tumors. B, genes
mostly under-expressed in tumors with the late relapse yolk sac tumors.
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 1 (GJB1, connexin 32) is the most over-expressed gene in yolk
sac tumors (Table 1). Mutations in the GJB1 gene are respon-
sible for the majority of cases of X-linked Charcot-Marie-Tooth
disease. Connexin expression is frequently decreased in neopla-
sia and may contribute to defective growth control and loss of
differentiated functions (24).
The genes of acyl-CoA dehydrogenase (C-2 to C-3 short
chain; ACADS) are the most differentially under-expressed in
yolk sac tumors. The acyl-CoA dehydrogenases (ACDs) are a
family of mitochondrial flavoenzymes required for fatty acid
-oxidation and branched-chain amino acid degradation. The
defects of ACDs in isoleucine and valine catabolism have been
proposed in clinically diverse patients with an abnormal pattern
of metabolites in their urine. In ACDs deficiency, the maternal
serum and amniotic fluid concentrations of -fetoprotein were
elevated (25). This is a very interesting observation because
there is a similar elevation of serum -fetoprotein in yolk sac
tumors.
ACADS and immunoglobulin heavy constant 3 are the
most over-expressed in embryonal carcinomas. Interestingly,
ACADS is the most under-expressed gene in yolk sac tumors but
is the most up-regulated gene in embryonal carcinomas. Immu-
noglobulin heavy chain has a relationship with multiple my-
eloma and plasma cell leukemia (26). Immunoglobulin genes
including immunoglobulin heavy constant 3 may play impor-
tant roles in embryonal carcinoma.
Differentially under-expressed genes in the embryonal car-
cinoma are GPC3 and gap junction protein 1. GPC3 is a
membrane-bound heparin sulfate proteoglycan. The GPC3 gene
is located at Xq26, frequently deleted in advanced ovarian
cancer cell lines (27). Expression of GPC3 is also silenced in
human breast cancer (28) and decreased in human gastric cancer
(29). In contrast, the expression of GPC3 in Wilms’ tumor,
hepatoblastoma, and hepatocellular carcinoma were increased
(30, 31). In our study, expression of GPC3 and Gap junction
protein 1 in yolk sac tumors was increased. These results show
some of the molecular genetic differences between yolk sac
tumors and embryonal carcinomas.
Matrix Gla protein (MGP) is the most over-expressed gene
in teratomas (Table 3). MGP is a vitamin-K-dependent protein
and is synthesized in a variety of tissues such as lung, heart,
kidney, cartilage, and bone. MGP mRNA levels have been
found to be elevated in a breast cancer cell lines, 600 polyeth-
ylenimine, primary renal-cell carcinomas, prostate carcinomas,
and testicular germ-cell tumors (32, 33).
PNET is a malignant, small, round cell tumor that exhibits
neuroepithelial differentiation. The histological designation of
PNETs in the testis (neuroblastoma or medulloepithelioma) did
Table 5 Differentially expressed genes in late relapse nonseminomatous germ cell tumor of testes (NSGCTT)s
Accession ID Gene name Fold changea P
R02346 Small nuclear ribonucleoprotein 70kD polypeptide 4.3 0.0200
AA775872 Glypican 3 4.1 0.0360
H50323 Fatty acid synthase 3.9 0.0045
AA858026 Serine (or cysteine) proteinase inhibitor, clade A member 5 3.3 0.0500
AA233070 KIAA0552 KINESIN-RELATED 3.0 0.0066
AA844124 ESTs 2.5 0.0200
T64469 p8 protein (candidate of metastasis 1) 2.2 0.0140
AA497051 Sialyltransferase 2.3 0.0390
AA456975 Apolipoprotein D 3.3 0.0450
AA447978 Aldehyde dehydrogenase 1 family, member A2 3.6 0.0290
AA291163 Glutaredoxin (thioltransferase) 4.0 0.0036
a Fold change indicates late relapse NSGCTTs and primitive neuroectodermal tumors have relatively higher or lower expression of this fold
change compared to early relapse NSGCTTs and primitive neuroectodermal tumors studied.
Table 6 Differentially expressed genes in late relapse yolk sac tumors
Accession ID Gene name Fold changea P
H99813 Glutathione S-transferase  1 (GSTT1) 6.0 0.0160
AA844124 ESTs 4.0 0.0430
H50323 Fatty acid synthase 3.9 0.0320
AA233070 KIAA0552 gene product 3.7 0.0190
T67442 HIC1-related gene on chromosome 22 3.0 0.0082
AA421269 Phosphatidylinositol 4-kinase, catalytic,  polypeptide 2.8 0.0380
AA196393 EF-HAND CALCIUM BINDING 2.4 0.0250
AA485373 Cathepsin D (lysosomal aspartyl protease) 2.5 0.0330
H96654 pp21 homolog 3.0 0.0400
AA424568 ADP-ribosylation factor-like 5 4.3 0.0088
R95691 Trinucleotide repeat containing 3 5.3 0.0300
N57754 Trinucleotide repeat containing 3 5.4 0.0170
T61271 Phospholipase A2, group IIA 9.7 0.0150
a Fold change indicates late relapse yolk sac tumors have relatively higher or lower expression of this fold change compared to early relapse yolk
sac tumors studied.
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not predict which tumor metastasized. Extratesticular PNETs in
patients with testicular germ-cell tumors are usually fatal, but
patients with neuroblastomatous metastases may have a more
prolonged course (4).
Neuronal pentraxin II and ubiquitin COOH-terminal ester-
ase L1 (UCHL1) are the most over-expressed genes in the
PNETs (Table 4). The existence of a family of pentraxin pro-
teins that are expressed in the brain, and other tissues may play
important roles in the uptake of extracellular material (34).
Protein gene product 9.5 (PGP 9.5), most likely identical to
UCHL1, is a major constituent of cytoplasmic polypeptides in
neurons. There is immunoreactive PGP 9.5 in many neuroen-
docrine cells, in spermatogonia, Leydig cells of the testis, ova,
and some cells of the corpus luteum (35). PGP 9.5 is also highly
expressed in peripheral PNET cell lines and embryonic tumors
(36). These findings are also consistent with our gene expression
profiling results.
Serine protease inhibitor Kunitz type 2 (SPINT2) and
RNase inhibitor-related are the most differentially under-ex-
pressed genes in the PNETs. SPINT2 is down-regulated in
normal human fibroblast MRC-5 cells expressing an activated
H-ras oncogene and in the human fibrosarcoma cell line
HT1080 (37). The human RNase inhibitor 2 is expressly limited
to testis and may play critical roles in human spermatogenesis
(38).
Differentially Expressed Genes in Each Prognosis:
Late-Relapse and Early-Relapse NSGCTTs. To identify
differentially expressed genes in late-relapse NSGCTTs and
PNETs compared to early-relapse NSGCTTs and PNETs, we
first identified genes that were at least 2-fold up- or down-
regulated in at least 75% of the tumors. Next, we identified
genes that could distinguish between early- and late-relapse
samples. The six up-regulated and five down-regulated genes
that met the above criteria are summarized in Table 5. Both
previously known and unknown genes were found to be signif-
icantly up- or down-regulated in 19 tumors, but the change
values, both up and down, were small. The most over-expressed
gene in the late-relapse group is small nuclear ribonucleopro-
tein 70kD polypeptide. The U1–70kD small nuclear ribonucle-
oprotein auto antigen is a major target of B-cell responses in
patients with connective tissue diseases (39).
Glutaredoxin (GRX) and aldehyde dehydrogenase
(ALDH)-1 family member A2 are the most differentially under-
expressed genes in the late-relapse group. GRX, also known as
Fig. 2 Real-time relative quantitative PCR analysis of GSTT1 (A), FASN (B), phospholipase A2 group IIA (C), TNRC3 (D), glypican 3 (E), and
glutaredoxin (F). The left side bar in gray of each sample indicates the expression ratio of tumor to normal testis by real-time relative quantitative
PCR and the right side bar in white indicates the expression ratio by microarray experiments. Data grouped based on clinical parameters are given
as the mean and the SE. They are evaluated statistically using the Mann-Whitney U test. All real-time relative quantitative PCR data were consistent
with microarray data. GSTT1 was significantly highly expressed in late-relapse yolk sac tumors (P 
 0.016; A), but FASN was not significantly
different between late- and early-relapse yolk sac tumors (P 
 0.222; B). PA2IIA and TNRC3 were significantly under-expressed in late-relapse yolk
sac tumors (P 
 0.032 and 0.016, respectively; C and D). However, glypican 3 and glutaredoxin also were not significantly different between the
two groups. P 
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thioltransferase, is a small dithiol protein that has been shown to
be involved in regulating various cellular functions (40). AL-
DHs are a group of enzymes that catalyze the conversion of
aldehydes to the corresponding carboxylic acids. The expression
of ALDH-1 is higher in radioresistant cervical squamous cell
carcinomas cells (41). Generally, genes related to the cell func-
tion may play some role between the two categories.
Differentially expressed genes in late-relapse yolk sac tu-
mors are shown in Table 6. The seven up-regulated and six
down-regulated genes that met the criteria are summarized in
Table 6. The most over-expressed gene in late-relapse yolk sac
tumors is GSTT1. The glutathione S-transferases (GSTs) have
been implicated as susceptibility genes for a number of cancers.
The homozygous deletions of GSTT1 [GSTT1()] group had a
worse prognosis than either the homozygous or heterozygous
for GSTT1 [GSTT1()] group in acute myeloid leukemia (42).
On the other hand, the GSTT1() genotype conferred the re-
duction in risk of relapse compared to the GSTT1() in children
with acute lymphoblastic leukemia (43, 44). Furthermore,
GSTT1() was associated with decreased time to the next
primary tumor presentation in the basal cell carcinoma (45). Our
results suggest that GSTT1 may play an important role for the
relapse frequencies of yolk sac tumors.
Phospholipase A2 group IIA (PLA2IIA) is the most differ-
entially under-expressed gene in late-relapse yolk sac tumors.
On the other hand, it is the most differentially over-expressed
gene in early-relapse yolk sac tumors. This enzyme releases free
fatty acids through catalysis of membrane in mammalian cells.
The product arachidonic acid is metabolized to produce pros-
taglandins and leukotrienes that mediate a diverse array of
biological activities including inflammation, mitogenesis, and
tumor cell invasion. PA2IIA can generate arachidonate from
cellular phospholipids. The expression of PA2IIA is elevated in
the prostatic cancer, and dysregulation of this enzyme may play
a role in prostatic carcinogenesis and progression (46, 47).
Furthermore, breast cancer patients with high PLA2 expression
have significantly shorter disease-free and overall survival than
those patients with low PLA2 expression (48). Therefore,
PLA2IIA may play some roles in the relapse of yolk sac tumors.
Real-Time Relative Quantitative PCR. All real-time
PCR data were consistent with microarray data (Fig. 2); how-
ever, in some cases the expression ratios calculated by real-time
PCR were different from those obtained by microarray. Spot
saturation and competitive hybridization during the microarray
experiments and the amplification methods of PCR may result
in these discrepancies.
Initial cisplatin-based combination chemotherapy is cura-
tive for many patients with metastatic testicular cancer. Subse-
quent second-line chemotherapy with high-dose carboplatin
plus etoposide will cure approximately half of the relapsing
patients. However, patients who experience a late relapse are
rarely cured with any type of chemotherapy (49). Our results
suggest that yolk sac tumor, with over-expressions of GSTT1
and under-expressed PLA2IIA, will have a risk of late-relapse
and drug resistance. For this group of patients, we need careful
follow-up on the patients after 2 years of initial management. In
contrast, yolk sac tumors with GSTT1 under-expression, and
PLA2IIA over-expression will have relapsed early, but cisplatin-
based combination chemotherapy has proven more effective.
In conclusion, we have identified gene expression alter-
ations that are specific for each type of NSGCT and PNET. The
identified genes may give insight into tumorigenesis and pro-
gression of these tumors. We have also identified gene expres-
sion alterations that distinguish between early- and late-relapse
yolk sac tumors. This may have important clinical implications
because the late relapse patients may require a different ap-
proach. In addition, some of these discriminating genes may
give potential insights into new drug targets.
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